Delivery Order 75F40120D00026-75F40121F19002

Award Date 9/30/21
Potential Completion Date 9/29/23
Potential Value $25M
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Falls Church, VA 22042, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Food and Drug Administration awarded a $5,273,171.50 delivery order contract to Iqvia Government Solutions Inc. to conduct surveillance activities for the safety and effectiveness of biologics. This contract is part of the BEST Initiative, a larger indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle for data tools and infrastructure to support surveillance of biologics. Iqvia Government Solutions is a for-profit organization that has...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $2.9 million delivery order to International Business Machines Corporation (IBM) under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) multiple award contract. The delivery order is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics, as part of HHS FDA's BEST Initiative. Major...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $13.2 million delivery order contract to International Business Machines Corporation (IBM) under the Biologics Effectiveness and Safety (BEST) Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract calls for IBM to provide data, tools, and infrastructure to support HHS FDA's BEST Initiative for surveillance of...
This is a $6,155,378.96 time and materials contract awarded by the Food and Drug Administration (FDA) to Iqvia Government Solutions Inc. for the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative #3: Health Care Data Sources for Surveillance of Biologics (BEST 3). The contract, which runs through September 29, 2025, is not set aside. Iqvia, a leading provider of healthcare data, analytics, and related services to federal agencies, will...
The Department of Health and Human Services Food and Drug Administration awarded a $1.7 million delivery order against the BEST Initiative - Data Sources for Surveillance of Biologics master IDIQ to CVS Health Clinical Trial Services LLC. The order is for BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS: "BEST 3": HEALTHCARE PATIENT DATA. CVS Health Clinical Trial Services, a subsidiary of CVS Health Corporation, will provide...
This is a $5,967,111.25 delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to IQVIA Government Solutions Inc., a provider of healthcare data, analytics, and related services to U.S. federal agencies. The contract was awarded under the FDA's BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics indefinite delivery, indefinite quantity (IDIQ) contract vehicle. The contract is for the development and...
This is a $2,442,983.29 time-and-materials contract awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Iqvia Government Solutions Inc., a for-profit provider of healthcare data, analytics, and related services to federal agencies. The contract is for the Biologics Effectiveness and Safety (BEST) Initiative, which involves blood and blood products safety surveillance. No set-aside was used. Iqvia has held several past and current IDIQ contracts with the...
The Department of Health and Human Services, Food and Drug Administration awarded a $24,519,103.59 Delivery Order contract to CVS Health Clinical Trial Services LLC, a subsidiary of CVS Health Corporation. The contract supports the BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS, which involves providing data sources and conducting surveillance of biological drug safety. The contract is a Time and Materials type with a period of performance...
This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration to the International Business Machines Corporation (IBM) on September 24, 2019. The $5,622,942.08 time and materials contract is a delivery order under the BEST Initiative - Data Tools and Infrastructure for Surveillance of Biologics master IDIQ contract vehicle. The objective is for IBM to conduct surveillance activities to assess the safety and effectiveness of biologics. This work...
This federal contract award to The Lewin Group, Inc., a subsidiary of UnitedHealth Group Incorporated, is a $508,000.00 firm fixed-price purchase order to provide health care and human services consulting to the U.S. government. The award has no set-aside designation and was issued on September 13, 1996, with a completion date of May 31, 2001. The Lewin Group specializes in policy research, economic analysis, and business strategy services focused on improving health care programs and...

The Food and Drug Administration (FDA) awarded a $24,583,221.15 delivery order contract to The Lewin Group, Inc. (a subsidiary of UnitedHealth Group Incorporated), to support the BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS. This contract is a task order under the $50 million BEST Initiative - Data Sources for Surveillance of Biologics indefinite-delivery/indefinite-quantity (IDIQ) contract, which provides longitudinal data sources needed to monitor the post-market safety and effectiveness of biologics products regulated by the FDA. The contract has a period of performance through September 29, 2023 and utilizes a time and materials pricing type. There is no set-aside designation for this award.

Generated 7/11/24, 9:44 AM